#EULAR2026 LB0005 More promising news in #PMR. Phase 3 RCT of Baricitinib + GC Taper in N=46: Part 1: BARI vs PBO 65% vs 17% GC-Free Remission at WK16 2: PBO-BARI improved response 17% to 65% at WK28 3: Lower remission rate in those stopped BARI vs continued at WK44 @RheumNow https://t.co/D77aHcACJE